-
Je něco špatně v tomto záznamu ?
Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?
R. Vrzal, A. Doricakova, A. Novotna, P. Bachleda, M. Bitman, P. Pavek, Z. Dvorak
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antikonvulziva toxicita MeSH
- cholekalciferol farmakologie MeSH
- extracelulárním signálem regulované MAP kinasy genetika metabolismus MeSH
- HEK293 buňky MeSH
- hepatocyty účinky léků MeSH
- histondeacetylasa 1 biosyntéza genetika MeSH
- kyselina valproová toxicita MeSH
- lidé MeSH
- luciferasy genetika MeSH
- messenger RNA biosyntéza genetika MeSH
- osteomalacie chemicky indukované patologie MeSH
- plazmidy genetika MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- receptory kalcitriolu účinky léků MeSH
- steroidhydroxylasy biosyntéza genetika MeSH
- steroidní receptory účinky léků MeSH
- transfekce MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- western blotting MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Valproic acid (VPA) is a wide spread anticonvulsant and mood-stabilizing agent, the use of which is associated with hepatotoxicity, bone marrow suppression and osteomalacia. In the current paper we propose a possible mechanism of VPA-induced osteomalacia involving accelerated catabolism of 1α,25(OH)(2)-vitamin D3 (VD3) due to increased expression of CYP24. We demonstrate that VPA strongly potentiates CYP24 mRNA expression by VD3 in human hepatocytes (HH) and in human embryonic kidney cells (HEK293). By the method of gene reporter assay we found that VPA increases basal and VD3-inducible activity of CYP24 promoter (pCYP24-luc) in human liver adenocarcinoma (HepG2) and in HEK293 cells in dose-dependent manner. In order to delineate the role of inhibitory effects of VPA on histone deacetylase 1 (HDAC1), we compared the effects of VPA with trichostatin A (TSA) on basal and inducible levels of CYP24 mRNA and pCYP24-luc transactivation. Transactivation of CYP24 promoter by VD3 was enhanced in the presence of both TSA and VPA. In contrast, VD3-inducible expression of CYP24 mRNA was enhanced by VPA but not by TSA, implying that HDAC1 inhibition is not the major reason for VPA effects on CYP24. We examined the effects of VPA on mitogen-activated protein kinases as the important transcriptional regulators of VDR. VPA activated extracellular signal-regulated kinase (ERK) but not c-Jun-N-terminal kinase (JNK) and p38 MAPKs. In conclusion, VPA enhances transcriptional activity of VDR and increases expression of CYP24 mRNA in the presence of VD3 in physiological concentrations. The mechanism involves activation of ERK and partly the inhibition of HDAC1.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026611
- 003
- CZ-PrNML
- 005
- 20250318105606.0
- 007
- ta
- 008
- 120816s2011 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.toxlet.2010.11.008 $2 doi
- 035 __
- $a (PubMed)21115105
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vrzal, Radim $7 xx0118949 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic. radim.vrzal@email.cz
- 245 10
- $a Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? / $c R. Vrzal, A. Doricakova, A. Novotna, P. Bachleda, M. Bitman, P. Pavek, Z. Dvorak
- 520 9_
- $a Valproic acid (VPA) is a wide spread anticonvulsant and mood-stabilizing agent, the use of which is associated with hepatotoxicity, bone marrow suppression and osteomalacia. In the current paper we propose a possible mechanism of VPA-induced osteomalacia involving accelerated catabolism of 1α,25(OH)(2)-vitamin D3 (VD3) due to increased expression of CYP24. We demonstrate that VPA strongly potentiates CYP24 mRNA expression by VD3 in human hepatocytes (HH) and in human embryonic kidney cells (HEK293). By the method of gene reporter assay we found that VPA increases basal and VD3-inducible activity of CYP24 promoter (pCYP24-luc) in human liver adenocarcinoma (HepG2) and in HEK293 cells in dose-dependent manner. In order to delineate the role of inhibitory effects of VPA on histone deacetylase 1 (HDAC1), we compared the effects of VPA with trichostatin A (TSA) on basal and inducible levels of CYP24 mRNA and pCYP24-luc transactivation. Transactivation of CYP24 promoter by VD3 was enhanced in the presence of both TSA and VPA. In contrast, VD3-inducible expression of CYP24 mRNA was enhanced by VPA but not by TSA, implying that HDAC1 inhibition is not the major reason for VPA effects on CYP24. We examined the effects of VPA on mitogen-activated protein kinases as the important transcriptional regulators of VDR. VPA activated extracellular signal-regulated kinase (ERK) but not c-Jun-N-terminal kinase (JNK) and p38 MAPKs. In conclusion, VPA enhances transcriptional activity of VDR and increases expression of CYP24 mRNA in the presence of VD3 in physiological concentrations. The mechanism involves activation of ERK and partly the inhibition of HDAC1.
- 650 _2
- $a antikonvulziva $x toxicita $7 D000927
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a cholekalciferol $x farmakologie $7 D002762
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a extracelulárním signálem regulované MAP kinasy $x genetika $x metabolismus $7 D048049
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a hepatocyty $x účinky léků $7 D022781
- 650 _2
- $a histondeacetylasa 1 $x biosyntéza $x genetika $7 D056284
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a luciferasy $x genetika $7 D008156
- 650 _2
- $a osteomalacie $x chemicky indukované $x patologie $7 D010018
- 650 _2
- $a plazmidy $x genetika $7 D010957
- 650 _2
- $a messenger RNA $x biosyntéza $x genetika $7 D012333
- 650 _2
- $a receptory kalcitriolu $x účinky léků $7 D018167
- 650 _2
- $a steroidní receptory $x účinky léků $7 D011987
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a steroidhydroxylasy $x biosyntéza $x genetika $7 D013250
- 650 _2
- $a transfekce $7 D014162
- 650 _2
- $a kyselina valproová $x toxicita $7 D014635
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vávrová, Aneta $7 _AN077313 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic. radim.vrzal@email.cz
- 700 1_
- $a Novotná, Aneta $7 _AN077312 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic. radim.vrzal@email.cz
- 700 1_
- $a Bachleda, Petr, $d 1954- $7 jn20020716344 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic. radim.vrzal@email.cz
- 700 1_
- $a Bitman, Michal $7 xx0330075 $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Pávek, Petr $7 xx0093070 $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Dvořák, Zdeněk, $d 1974- $7 xx0118950 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 11, 783 71 Olomouc, Czech Republic. radim.vrzal@email.cz
- 773 0_
- $w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 200, č. 3 (2011), s. 146-153
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21115105 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20250318105603 $b ABA008
- 999 __
- $a ok $b bmc $g 948653 $s 783957
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 200 $c 3 $d 146-153 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537
- LZP __
- $b NLK122 $a Pubmed-20120816/11/01